ENTITY
CARsgen Therapeutics

CARsgen Therapeutics (2171 HK)

44
Analysis
Health Care • China
CARsgen Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, researching, and developing innovative CAR T-cell therapies. The company's pipeline includes therapies for hematological malignancies, solid tumors, and autoimmune diseases, such as CT053 for multiple myeloma. It is headquartered in Shanghai, China, and was founded in 2014.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x